

SRS 2026 Uro-Oncology Program

July 25, 2026, 2026

Day 1 – Telesurgery: Setting the Stage and Core Domains

07:50 – 08:00 Welcome and Introduction to the Course

08:00 – 08:20 State-of-the-Art in Prostate Cancer (2025–2026)

08:20 – 9:50 Module 1 – Prostate Cancer Screening, Diagnosis, and Imaging

- 08:20-08:33 Prostate Cancer Screening and Negative Impacts of Non-Screening Recommendations (DOI: 10.1056/NEJMoa2503223)
- 08:33-08:48 Genetic Test Applications in PCa Diagnosis and Management (Decipher, 4K, PHI, GPS, Urinary Markers, Exosomes, Etc.)
- 08:48-09:01 Current Role of MRI and PET Scan in Prostate Cancer Diagnosis and Staging (PSMA, Axumin, Fluoride, Etc.)
- 09:01-09:14 Current Role of Artificial Intelligence in Prostate Cancer Detection and Image Interpretation
- 09:14-09:27 Prostate Biopsy Techniques (Transrectal, Transperineal, US Fusion, MRI Fusion): Which One Should I Do?
- 09:27-09:40 Current Role of Artificial Intelligence in Optimizing the Pathological Analysis
- 09:40-09:50 Module 1 Discussion

9:50 – 11:00 Module 2 – Localized and Intermediate-Risk Localized Prostate Cancer

- 09:50-10:05 Active Surveillance: Optimal Candidates, Protocols, and When to Start Treatment. Is Gleason 7 a Safe Candidate for AS?
- 10:05-10:20 Surgical Outcomes for Localized PCa: Oncologic and Functional Data From High-Volume Centers
- 10:20-10:35 Advances in Radiotherapy to Treat Localized Disease: Moderate vs. Ultra-Hypofractionation (CHHiP, PACE-B, HYPO-RT-PC)
- 10:35-10:50 Focal Therapy Applications to Treat Localized Disease (Selection Criteria, Outcomes, and Follow-Up Protocols)
- 10:50-11:00 Module 2 Discussion

11:00 – 12:10 Module 3- High-Risk and Locally Advanced Prostate Cancer

- 11:00-11:12 Genomic Test Applications in High-Risk Patients and Patients With a Family History of PCa: When Should I Order?
- 11:12-11:24 What’s the Treatment of Choice in High-Risk Disease: Surgery vs. Radiation Therapy (Plus ADT)?
- 11:24-11:36 Use of AI and Transcriptomics to Personalize Therapy in Newly Diagnosed Advanced Prostate Cancer
- 11:36-11:48 The Role of Post-Prostatectomy Radiation in High-Risk Disease Based on Clinical, Pathologic, and Molecular Characteristics
- 11:48-12:00 The Role and Extent of Lymph Node Dissection in the PET-PSMA Era
- 12:00-12:10 Module 3 Discussion

12:10-12:40 Clinical Cases of High-Grade PCa: Multidisciplinary Approach

12:40 – 13:10 Lunch

13:10 – 14:30 Module 4 – Recurrent Disease After Local Treatment

- 13:10-13:20 Applications of PSMA PET or Other Radiotracers in Staging PCa Recurrence
- 13:20-13:30 Biochemical Recurrence After RP: When to Offer Observation? When to Offer Isolated XRT? When to Offer XRT Combined With ADT? When to Offer Systemic Treatment?
- 13:30-13:40 Post-RT Recurrence: Should PSMA-Positive Lesions Be Biopsied Before Salvage?
- 13:40-13:50 Selecting the Best Salvage Treatment After Radiotherapy Failure for Localized Prostate Cancer: Surgery vs. RT vs. Ablation
- 13:50-14:00 Managing PCa With Lymph Node Recurrence: How to Optimize Results? Surgery vs. RT (With or Without ADT-Based Regimens) Protocols
- 14:00-14:20 Clinical Cases of Recurrent PCa: Multidisciplinary Approach
- 14:20-14:30 Module 4 Discussion

14:30 – 15:30 Module 5 – Metastatic Disease

- 14:30-14:42 M1CSPC Oligometastatic: Definition and Evolution of the OMD Concept
- 14:42-14:55 What's the Optimal Treatment of Metachronous Oligometastatic Disease: Focal Treatment vs. Systemic Treatment vs. Both
- 14:55-15:07 The Role of Local Treatment Including Radiation Therapy or Surgery in Low-Volume Metastatic Disease
- 15:07-15:20 Clinical Cases of Oligometastatic PCa: Multidisciplinary Approach
- 15:20-15:30 Module 5 Discussion

15:30 – 17:30 Module 6 – Metastatic Disease

- 15:30-15:40 M1CSPC – Optimal Systemic Management of Low-Volume Metastatic Castration-Sensitive PCa
- 15:40-15:50 M1CSPC – Optimal Systemic Management of High-Volume Metastatic Castration-Sensitive PCa
- 15:50-16:00 M1CSPC – The Role of Focal Treatment Combined With Systemic Treatment vs. Systemic Treatment Alone in Addressing Metastatic Castration-Sensitive PCa
- 16:00-16:10 M1CSPC – Ongoing Studies Evaluating New Agents Beyond ADT in the Metastatic Setting
- 16:10-16:20 Clinical Cases of M1CSPC: Multidisciplinary Approach
- 16:20-16:30 PARP Inhibitors in M1CRPC – Trials, Results, and Best Candidates (PROfound, PROpel, MAGNITUDE, TALAPRO-2 Data)
- 16:30-16:40 M1CRPC – Radioligand Therapy (177Lu-PSMA-617, Ac-225): Patient Selection, Sequencing, and Safety
- 16:40-16:50 M1CRPC – Ongoing Studies Evaluating New Agents in the M1CRPC Setting
- 16:50-17:00 Clinical Cases of M1CRPC: Multidisciplinary Approach
- 17:00-17:30 Metastatic Cases Discussion